5-Amino-1MQ

This compound is not a peptide, though it is sold and discussed alongside them and usually appears in "peptide" catalogues. It is a small-molecule quinolinium salt, and that misfiling is itself worth knowing.

Not approved by any regulator, anywhere, for any indication. No investigational new drug programme or registered human trial was identified. It is not on FDA’s Category 2 list, was never nominated for or reviewed at any compounding advisory committee meeting, and is not on the 503A Bulks List. It is not a lawful dietary supplement ingredient: a synthetic small molecule with no history of use in the food supply and no new-dietary-ingredient notification identified. It is not named anywhere on the WADA 2026 Prohibited List; it would arguably fall within the S0 catch-all for non-approved pharmacological substances, but it is not named and it should not be described as banned.

Claims — stated as claims — include fat loss and reduction in fat cell size, increased NAD+ levels, reversal of metabolic slowdown, improved insulin sensitivity, muscle performance and strength gains, "exercise mimetic" effects, anti-aging and longevity.

There are no human studies of 5-amino-1MQ, and no human trial of any NNMT inhibitor was identified in the peer-reviewed literature or in trial registries. Unlike BPC-157, TB-500 and MOTS-c, that absence rests on the research package’s own searches rather than on a regulator’s systematic review, because nobody has ever nominated this compound for regulatory consideration — and that is the finding for this entry. Every search for human evidence, regulatory status or enforcement returned almost exclusively vendor and content-marketing material. The authoritative-source vacuum here is more complete than for any other compound in this cluster while the marketing volume is among the highest.

The evidence that does exist is mice and cell culture. The pivotal study treated nine mice per group for eleven days and reported weight loss against weight gain in controls, fat pad mass and adipocyte size down by about a third and plasma cholesterol down by about 30%; the authors describe it as proof-of-concept, and the dose-escalation study that set its dose used two mice. A 2024 aged-mouse study is the source of the "exercise mimetic" and strength claims, and in it the directly measured contractile endpoint — plantarflexor peak torque — was null. All published pharmacokinetics are in rats.

Safety is unknown in the strongest sense. No human study of any kind exists, so there is no human safety data at any dose, route or duration. No regulator has reviewed it. The animal safety record is incidental rather than systematic: the pivotal mouse study states there were no observable adverse effects but reports no formal toxicity panel, and no acute, repeat-dose, genotoxicity, reproductive, developmental or carcinogenicity study was identified. A mechanistic concern worth stating as a concern rather than a documented harm: NNMT and the S-adenosylmethionine methylation cycle are involved in broad epigenetic regulation, and NNMT is also studied as an oncology target with context-dependent effects. There is also no product-quality data at all — 5-amino-1MQ was not among the fourteen compounds in the grey-market purity survey, and no analytical survey of marketed product was found, so its identity, purity and contaminant profile are entirely uncharacterised.